GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Equity-to-Asset

INBX (Inhibrx Biosciences) Equity-to-Asset : 0.80 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Inhibrx Biosciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $178.47 Mil. Inhibrx Biosciences's Total Assets for the quarter that ended in Sep. 2024 was $222.56 Mil.

The historical rank and industry rank for Inhibrx Biosciences's Equity-to-Asset or its related term are showing as below:

INBX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.44   Med: -0.31   Max: 0.85
Current: 0.8

During the past 2 years, the highest Equity to Asset Ratio of Inhibrx Biosciences was 0.85. The lowest was -0.44. And the median was -0.31.

INBX's Equity-to-Asset is ranked better than
66.27% of 1509 companies
in the Biotechnology industry
Industry Median: 0.67 vs INBX: 0.80

Inhibrx Biosciences Equity-to-Asset Historical Data

The historical data trend for Inhibrx Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Equity-to-Asset Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23
Equity-to-Asset
-0.44 -0.31

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial - -0.31 -0.38 0.85 0.80

Competitive Comparison of Inhibrx Biosciences's Equity-to-Asset

For the Biotechnology subindustry, Inhibrx Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibrx Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's Equity-to-Asset falls into.


Inhibrx Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Inhibrx Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-7.973/26
=-0.31

Inhibrx Biosciences's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=178.467/222.562
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibrx Biosciences  (NAS:INBX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Inhibrx Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Equity-to-Asset
Comparable Companies
PROK DRTS ZNTL ATAI NAUT PGEN LXEO IKT DMAC MGNX VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Website
https://www.inhibrx.com
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.